Skip to main content

$0.550 0.010 (1.85%)

High

$0.56

Low

$0.54

Trades

245

Turnover

$454,189

Volume

827,047
30 June 2023 at 4:59pm
Register to track OPT and receive email alerts.
Subject
OPT Ann: Appendix 2A Update

OPT Ann: Cleansing Notice

OPT Ann: Appendix 2A

OPT Ann: Opthea opens patient enrollment in the Asia-Pacifi Region

OPT Ann: Results of Meeting

OPT Ann: Opthea Corporate Presentation - October 2021

OPT Ann: Opthea Chairman's Address to the 2021 Annual General Meeting

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Opthea's Phase 3 open for patient recruitment in Europe

OPT Ann: Change in substantial holding

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Becoming a substantial holder

OPT Ann: Addendum to Notice of Meeting

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Notice of Annual General Meeting and Proxy Form

OPT Ann: Opthea Appendix 4G Corporate Governance Statement amended

OPT Ann: Opthea to present at September Investor Conferences

OPT Ann: Opthea Appendix 4G Corporate Governance Statement

OPT Ann: Opthea reports Fiscal Year 2021 Results and Highlights

OPT Ann: Opthea Appendix 4E and Annual Report

OPT Ann: Becoming a substantial holder

OPT Ann: Becoming a substantial holder

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Becoming a substantial holder

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Becoming a substantial holder

OPT Ann: Opthea to present at H.C Wainwright Ophthalmology Conference

OPT Ann: Opthea expands Phase 3 for OPT-302 into Canada

OPT Ann: Ceasing to be a substantial holder

OPT Ann: Opthea's OPT-302 Granted Fast-Track for wet AMD

OPT Ann: Change in substantial holding

OPT Ann: Change in substantial holding

OPT Ann: Cleansing Notice

OPT Ann: Application for quotation of securities - OPT

OPT Ann: Change in substantial holding

OPT Ann: Change in substantial holding

OPT Ann: Proposed issue of securities - OPT

OPT Ann: Opthea Appoints Company Secretary and VP of Finance

OPT Ann: Initial Director's Interest Notice-JH

OPT Ann: Initial Director's Interest Notice-JR

OPT Ann: Director Appointment/Resignation

OPT Ann: Change in substantial holding

OPT Ann: Becoming a substantial holder

OPT Ann: Opthea Company Secretary Resignation

OPT Ann: Opthea Receives FDA Waiver for Pediatric Study Plan

OPT Ann: Change in substantial holding

OPT Ann: Appendix 2A Update

OPT Ann: Cleansing Notice

OPT Ann: Appendix 2A

Register to track OPT and receive email alerts.

Similar Companies

CSL ...
CSL
CUV
IMM
IMU
MSB
PAR
PYC
RAC
TLX